Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or… read more.
A drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no targeted treatments, according to a new… read more.
UCSF Study finds that changes in daily salt intake may explain eczema flares. A high sodium diet may increase the risk of eczema, according to researchers at UC… read more.
Children and young adults with allergies or eczema who have difficulty swallowing may have eosinophilic esophagitis. A review published in CMAJ (Canadian Medical Association Journal) provides guidance on how to… read more.
People with atopic (allergic) diseases like asthma or eczema may be at heightened risk of the painful and often disabling joint condition, osteoarthritis, finds research published online in… read more.
Atopic dermatitis (AD), also called atopic eczema, is the most common, chronic, recurrent, inflammatory disorder of the skin, and it affects 5–30% of children worldwide. An analysis in… read more.
Treatment with the biologic drug dupilumab brings relief to children younger than 6 years-old who are suffering with moderate-to-severe atopic dermatitis (eczema) The findings were published on Sept…. read more.
The Best Emollients for Eczema trial has found that no one type of moisturiser is better than another. This study, the first in the world to directly compare… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
